Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$52.05 - $65.0 $5.73 Million - $7.16 Million
-110,083 Reduced 34.78%
206,448 $12.4 Million
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $7.96 Million - $19.2 Million
316,531 New
316,531 $19.2 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $661M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Suvretta Capital Management, LLC Portfolio

Follow Suvretta Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Suvretta Capital Management, LLC with notifications on news.